An2 showed high targeting to low-density lipoprotein receptor-related protein on the blood–brain barrier (BBB), while anti-CD133 was capable of targeting toward CD133, which was highly expressed on the cancer stem cells of glioblastoma multiforme. The gene discussed is PROM1; the disease is cancer.